Related Experiment Videos
[Clinical features and treatment of refractory epilepsy in children]
1Department of Pediatrics, National Nishibeppu Hospital.
Insights
Refractory epilepsy in children often presents with early onset and developmental issues. Standard drug treatments are frequently ineffective, necessitating sequential trials of various medications and comprehensive management strategies.
Area of Science:
- Pediatric Neurology
- Epileptology
- Clinical Pharmacology
Background:
- Refractory epilepsy in children is characterized by symptomatic localization-related epilepsy, particularly frontal lobe epilepsy.
- Early onset (under 3 years) and developmental retardation are common clinical features.
- Initial treatments with first-choice drugs show variable efficacy in idiopathic epilepsy but are often ineffective in refractory cases.
Purpose of the Study:
- To evaluate the effectiveness of sequential drug trials in children with refractory epilepsy.
- To highlight the challenges in managing pediatric refractory epilepsy.
- To emphasize the need for comprehensive management strategies beyond pharmacotherapy.
Main Methods:
- Retrospective analysis of treatment outcomes in pediatric patients with refractory epilepsy.
- Assessment of seizure control rates with various antiepileptic drugs (AEDs) in refractory cases.
- Review of clinical features and management approaches for refractory epilepsy.
Main Results:
- Standard first-choice drugs (e.g., valproic acid, carbamazepine) demonstrate limited efficacy in the refractory epilepsy group.
- Sequential trials of various AEDs yielded low seizure control rates: 10-17% for localization-related epilepsy and 9-20% for generalized epilepsy.
- Despite the development of new drugs, the incidence of refractory epilepsy in children remains a significant clinical challenge.
Conclusions:
- No single antiepileptic drug is consistently effective for refractory epilepsy in children.
- Sequential administration of diverse AEDs, irrespective of seizure type, is recommended.
- Comprehensive management, including daily life support and surgical interventions, is crucial for affected children.
Abstract:
Clinical features of refractory epilepsy in children are symptomatic localization-related epilepsy, especially frontal lobe epilepsy, the onset in young age less than 3 years-old, and complication of developmental retardation. The treatments usually start with one drug of choice for specific seizure type. In the idiopathic epilepsy group, valproic acid was effective in 82% of the patients with generalized epilepsy and in 45% of localization-related epilepsy while carbamazepine was effective in 71% and 67%, respectively. However, in the refractory group which did not react to the drugs of choice at the initial treatment and continued to have seizures, no specific drugs were effective. Therefore, various kind of drugs, new or old, should be tried in sequence irrespective of the type of seizures. The seizure control was attained only in 10% (in the cases of CZP), and 17% (CLB) in localization-related epilepsy and in 9% (VPA), 12% (NZP) and 20% (ZNS) in generalized one in the refractory group. Although new drugs developed, the patients with refractory epilepsy do not tend to decrease in frequency and overall management including daily life or surgical therapy is mandatory for the children with refractory epilepsy.